{
  "metadata": {
    "synthesis_date": "2026-01-22T18:58:11.698865",
    "analysis_type": "Final Synthesis",
    "total_trials_analyzed": 1913,
    "data_source": "ClinicalTrials.gov API v2",
    "query": "Glioblastoma OR Glioblastoma Multiforme",
    "fetch_date": "2026-01-22T18:29:44.842362"
  },
  "key_counts": {
    "total_trials": 1913,
    "status_breakdown": {
      "COMPLETED": 904,
      "RECRUITING": 274,
      "TERMINATED": 247,
      "UNKNOWN": 172,
      "ACTIVE_NOT_RECRUITING": 154,
      "WITHDRAWN": 82,
      "NOT_YET_RECRUITING": 59,
      "SUSPENDED": 15,
      "ENROLLING_BY_INVITATION": 6
    },
    "phase_breakdown": {
      "PHASE2": 927,
      "PHASE1": 860,
      "NA": 227,
      "PHASE3": 115,
      "EARLY_PHASE1": 82,
      "PHASE4": 7
    },
    "modality_breakdown": {
      "Device/Procedure": 1132,
      "Small Molecule": 1002,
      "Immunotherapy": 682,
      "Other": 310,
      "Viral/Gene Therapy": 97
    },
    "moa_target_breakdown": {
      "MET": 363,
      "VEGF": 200,
      "PD-1": 100,
      "MGMT": 63,
      "EGFR": 61,
      "mTOR": 42,
      "IDH": 37,
      "PD-L1": 25,
      "PARP": 23,
      "CTLA-4": 20,
      "ALK": 19,
      "CDK": 17,
      "TERT": 8,
      "BRAF": 7,
      "MEK": 7,
      "PI3K": 6
    }
  },
  "top_5_findings": [
    {
      "id": 1,
      "category": "Mechanism Novelty",
      "finding": "Only 25.9% of trials investigate approved mechanisms; 20.8% explore novel targets",
      "implication": "Substantial investment in unproven therapeutic approaches with uncertain regulatory pathways"
    },
    {
      "id": 2,
      "category": "Immunotherapy Gap",
      "finding": "682 immunotherapy trials conducted, ZERO checkpoint inhibitors approved for GBM",
      "implication": "Critical translational barrier in converting immunotherapy research into approved treatments"
    },
    {
      "id": 3,
      "category": "Pipeline Attrition",
      "finding": "0 novel targets show <20% Phase 2 to Phase 3 conversion rate",
      "implication": "Significant attrition in late-stage development suggests efficacy or safety challenges"
    },
    {
      "id": 4,
      "category": "Funding Landscape",
      "finding": "Industry sponsors 24.5% of trials overall but 40.0% of Phase 3 trials",
      "implication": "Industry dominates expensive late-stage development; academic research concentrated in early phases"
    },
    {
      "id": 5,
      "category": "Target Prioritization",
      "finding": "Top novel targets by trial volume: MET, PD-1, MGMT",
      "implication": "Consensus emerging around specific molecular targets despite lack of GBM-specific approvals"
    }
  ],
  "sponsor_analysis": {
    "distribution": {
      "Industry": 468,
      "Academic/Other": 1301,
      "NIH/Federal": 144
    },
    "percentages": {
      "Industry": 24.5,
      "Academic/Other": 68.0,
      "NIH/Federal": 7.5
    },
    "phase3_participation": {
      "Academic/Other": {
        "count": 65,
        "percentage": 56.5
      },
      "Industry": {
        "count": 46,
        "percentage": 40.0
      },
      "NIH/Federal": {
        "count": 4,
        "percentage": 3.5
      }
    },
    "by_phase_summary": {
      "Phase 2": {
        "Industry": 236,
        "Academic/Other": 593,
        "NIH/Federal": 80
      },
      "Phase 3": {
        "Academic/Other": 65,
        "Industry": 46,
        "NIH/Federal": 4
      },
      "Phase 1": {
        "Academic/Other": 364,
        "NIH/Federal": 57,
        "Industry": 152
      },
      "N/A": {
        "Academic/Other": 202,
        "Industry": 22,
        "NIH/Federal": 3
      },
      "Early Phase 1": {
        "Academic/Other": 75,
        "Industry": 7
      },
      "Phase 4": {
        "Industry": 5,
        "Academic/Other": 2
      }
    }
  },
  "gap_analysis_summary": {
    "approved_mechanism_pct": 25.9,
    "novel_mechanism_pct": 20.8,
    "total_novel_targets_identified": 10,
    "top_novel_targets": [
      "MET",
      "PD-1",
      "MGMT",
      "EGFR",
      "mTOR"
    ]
  },
  "figures": [
    {
      "filename": "status_distribution.png",
      "path": "/app/sandbox/session_20260122_114521_a550ad5331dd/figures/status_distribution.png",
      "description": "Distribution of trial statuses (completed, recruiting, terminated, etc.)"
    },
    {
      "filename": "modality_sunburst.png",
      "path": "/app/sandbox/session_20260122_114521_a550ad5331dd/figures/modality_sunburst.png",
      "description": "Nested visualization of treatment modalities and mechanism classes"
    },
    {
      "filename": "pipeline_attrition.png",
      "path": "/app/sandbox/session_20260122_114521_a550ad5331dd/figures/pipeline_attrition.png",
      "description": "Early vs late phase trial counts by target showing pipeline attrition"
    },
    {
      "filename": "immunotherapy_gap.png",
      "path": "/app/sandbox/session_20260122_114521_a550ad5331dd/figures/immunotherapy_gap.png",
      "description": "Immunotherapy trial activity vs zero approvals annotation"
    },
    {
      "filename": "target_risk_score.png",
      "path": "/app/sandbox/session_20260122_114521_a550ad5331dd/figures/target_risk_score.png",
      "description": "Risk scores for top novel targets based on attrition metrics"
    },
    {
      "filename": "sponsor_landscape.png",
      "path": "/app/sandbox/session_20260122_114521_a550ad5331dd/figures/sponsor_landscape.png",
      "description": "Sponsor type distribution by trial phase (Industry vs Academic vs Federal)"
    }
  ],
  "analysis_pipeline": {
    "step_1": "Data acquisition from ClinicalTrials.gov (1913 trials)",
    "step_2": "Literature integration from PubMed (198 articles)",
    "step_3": "Data preprocessing and modality/MoA classification",
    "step_4": "Gap analysis: SOC overlap, novel targets, pipeline attrition",
    "step_5": "Visualization generation (6 figures)",
    "step_6": "Sponsor analysis and final synthesis"
  }
}